Randomised clinical trial: Efficacy of the addition of a prokinetic, mosapride citrate, to omeprazole in the treatment of patients with non-erosive reflux disease - A double-blind, placebo-controlled study

Alimentary Pharmacology and Therapeutics

Volumn 33, Issue 3, 2011, Pages 323-332

  Miwa, H ^a   Inoue, K ^b   Ashida, K ^c   Kogawa, T ^d   Nagahara, A ^e   Yoshida, S ^f   Tano, N ^g   Yamazaki, Y ^h   Wada, T ⁱ   Asaoka, D ^f   Fujita, T ^j   Tanaka, J ^a   Shimatani, T ^k   Manabe, N ^l   Oshima, T ^a   Haruma, K ^l   Azuma, T ^m   Yokoyama, T ⁿ  

^a HYOGO COLLEGE OF MEDICINE   (Japan)

^b MATSUE RED CROSS HOSPITAL   (Japan)

^c SAISEIKAI NAKATSU HOSPITAL   (Japan)

^d Kogawa Clinic   (Japan)

^e JUNTENDO UNIVERSITY   (Japan)

^f Akashi City Hospital   (Japan)

^g Kyoritsu Hospital   (Japan)

^h National Institute of Technology Fukui College   (Japan)

ⁱ NAGOYA CITY UNIVERSITY   (Japan)

^j YODOGAWA CHRISTIAN HOSPITAL   (Japan)

^k HIROSHIMA INTERNATIONAL UNIVERSITY   (Japan)

^l KAWASAKI MEDICAL SCHOOL   (Japan)

^m KOBE UNIVERSITY   (Japan)

ⁿ NATIONAL INSTITUTE OF PUBLIC HEALTH   (Japan)

more..

Author keywords

[No Author keywords available]

Indexed keywords

MOSAPRIDE CITRATE; OMEPRAZOLE; PLACEBO;

ABDOMINAL PAIN; ADD ON THERAPY; ADULT; ARTICLE; BODY MASS; DIARRHEA; DISEASE DURATION; DISEASE SEVERITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON EROSIVE REFLUX DISEASE; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYMPTOMATOLOGY; VISUAL ANALOG SCALE;

EID: 78650864043     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2010.04517.x     Document Type: Article

References (42)

1. Sonnenberg A, El-Serag HB,. Clinical epidemiology and natural history of gastroesophageal reflux disease. Yale J Biol Med 1999; 3: 81-92.
2. Fujiwara Y, Arakawa T,. Epidemiology and clinical characteristics of GERD in the Japanese population. J Gastroenterol 2009; 44: 518-34.
3. Holtmann G, Maldonado-Lopez E, Haag S,. Heartburn in primary care: problems below the surface. J Gastroenterol 2004; 39: 1027-34.
4. Wang C, Hunt RH,. Medical management of gastroesophageal reflux disease. Gastroenterol Clin North Am 2008; 37: 879-99.
5. Heidelbaugh JJ, Nostrant TT, Kim C, Van Harrison R,. Management of gastroesophageal reflux disease. Am Fam Physician 2003; 68: 1311-8.
6. Galmiche JP, Stephenson K,. Treatment of gastroesophageal reflux disease in adults: an individualized approach. Dig Dis 2004; 22: 148-60.
7. Fock KM, Talley N, Hunt R, et al. Report of the Asia-Pacific consensus on the management of gastroesophageal reflux disease. J Gastroenterol Hepatol 2004; 19: 357-67.
8. Miwa H, Sasaki M, Furuta T, et al. Efficacy of rabeprazole on heartburn symptom resolution in patients with non-erosive and erosive gastro-oesophageal reflux disease: a multicenter study from Japan. Aliment Pharmacol Ther 2007; 26: 69-77.
9. Dean BB, Gano AD Jr, Knight K, et al. Effectiveness of proton pump inhibitors in nonerosive reflux disease. Clin Gastroenterol Hepatol 2004; 2: 656-64.
10. Pehlivanov N, Liu J, Mittal RK,. Sustained esophageal contraction: a motor correlate of heartburn symptom. Am J Physiol Gastrointest Liver Physiol 2001; 281: G743-51.
11. Ang TL, Fock KM, Ng TM, et al. A comparison of the clinical, demographic and psychiatric profiles among patients with erosive and non-erosive reflux disease in a multi-ethnic Asian country. World J Gastroenterol 2005; 11: 3558-61.
12. Miwa H, Minoo T, Hojo M, et al. Oesophageal hypersensitivity in Japanese patients with non-erosive gastro-oesophageal reflux diseases. Aliment Pharmacol Ther 2004; 20 (Suppl. 1): 112-7.
13. Nagahara A, Miwa H, Minoo T, et al. Increased esophageal sensitivity to acid and saline in patients with nonerosive gastro-esophageal reflux disease. J Clin Gastroenterol 2006; 40: 891-5.
14. Fass R,. Proton pump inhibitor failure-what are the therapeutic options? Am J Gastroenterol 2009; 2 (Suppl.): S33-8.
15. Fass R, Sifrim D,. Management of heartburn not responding to proton pump inhibitors. Gut 2009; 58: 295-309.
16. Champion MC,. Prokinetic therapy in gastroesophageal reflux disease. Can J Gastroenterol 1997; 11 (Suppl. B): 55B-65B.
17. Ramirez B, Richter JE,. Review article: promotility drugs in the treatment of gastro-oesophageal reflux disease. Aliment Pharmacol Ther 1993; 7: 5-20.
18. Achem SR, Robinson M,. A prokinetic approach to treatment of gastroesophageal reflux disease. Dig Dis 1998; 16: 38-46.
19. Ruth M, Finizia C, Cange L, et al. The effect of mosapride on oesophageal motor function and acid reflux in patients with gastro-oesophageal reflux disease. Eur J Gastroenterol Hepatol 2003; 15: 1115-21. (Pubitemid 37267228)
20. Geeraerts B, Vandenberghe J, Van Oudenhove L, et al. Influence of experimentally induced anxiety on gastric sensorimotor function in humans. Gastroenterology 2005; 129: 1437-44.
21. Vandenberghe J, Vos R, Persoons P, et al. Dyspeptic patients with visceral hypersensitivity: sensitization of pain specific or multimodal pathways? Gut 2005; 54: 914-9.
22. Bruera E, Belzile M, Neumann C, et al. A double-blind, crossover study of controlled-release metoclopramide and placebo for the chronic nausea and dyspepsia of advanced cancer. J Pain Symptom Manage 2000; 19: 427-35.
23. Chen CL, Lin HH, Chen MC, et al. Dyspeptic symptoms and water load test in patients with functional dyspepsia and reflux disease. Scand J Gastroenterol 2005; 40: 28-32.
24. Uemura N, Inokuchi H, Serizawa H, et al. Efficacy and safety of omeprazole in Japanese patients with nonerosive reflux disease. J Gastroenterol 2008; 43: 670-8.
25. Long JD, Orlando RC,. Nonerosive reflux disease: a pathophysiologic perspective. Curr Gastroenterol Rep 2008; 10: 200-7.
26. Kamiya T, Adachi H, Hirako M, et al. Impaired gastric motility and its relationship to reflux symptoms in patients with nonerosive gastroesophageal reflux disease. J Gastroenterol 2009; 44: 183-9.
27. Carmagnola S, Fraquelli M, Cantà P, et al. Relationship between acceleration of gastric emptying and oesophageal acid exposure in patients with endoscopy-negative gastro-oesophageal reflux disease. Scand J Gastroenterol 2006; 41: 767-72.
28. Seto Y, Kawashima K, Yoshida N, et al. Inhibitory effect of mosapride citrate, a 5-HT4 receptor agonist, on gastric distension-induced visceral pain behavior and abdominal striated muscle contraction in conscious rats. Gastroenterology 2005; 2: A671.
29. Kaneko H, Konagawa T, Kakumu S,. Visceral specific analgesic action of mosapride citrate, a gastroprokinetic drug, and its metabolite against gastric distension through a 5HT4 and HT3 receptor in conscious rats. Gastroenterology 2006; 2: A246.
30. Arai K, Takeuchi Y, Watanabe H, et al. Prokinetics influence the pharmacokinetics of rabeprazole. Digestion 2008; 78: 67-71.
31. Miyamoto M, Haruma K, Takeuchi K, et al. Frequency scale for symptoms of gastroesophageal reflux disease predicts the need for addition of prokinetics to proton pump inhibitor therapy. J Gastroenterol Hepatol 2008; 23: 746-51.
32. Vigneri S, Termini R, Leandro G, et al. A comparison of five maintenance therapies for reflux esophagitis. N Engl J Med 1995; 333: 1106-10.
33. Madan K, Ahuja V, Kashyap PC, et al. Comparison of efficacy of pantoprazole alone versus pantoprazole plus mosapride in therapy of gastroesophageal reflux disease: a randomized trial. Dis Esophagus 2004; 17: 274-8.
34. Kinoshita Y, Kobayashi T, Kato M, et al. The pharmacodynamic effect of omeprazole 10 mg and 20 mg once daily in patients with nonerosive reflux disease in Japan. J Gastroenterol 2006; 41: 554-61.
35. Dent J, Kahrilas PJ, Vakil N, et al. Clinical trial design in adult reflux disease: a methodological workshop. Aliment Pharmacol Ther 2008; 28: 107-26.
36. Mulak A,. Testing of visceral sensitivity. J Physiol Pharmacol 2003; 54 (Suppl. 4): 55-72.
37. Liang LX, Zhang Q, Qian W, et al. Antinociceptive property of tegaserod in a rat model of chronic visceral hypersensitivity. Chin J Dig Dis 2005; 6: 21-5.
38. Rodriguez-Stanley S, Zubaidi S, Proskin HM, et al. Effect of tegaserod on esophageal pain threshold, regurgitation, and symptom relief in patients with functional heartburn and mechanical sensitivity. Clin Gastroenterol Hepatol 2006; 4: 442-50.
39. Curran MP, Robinson DM,. Mosapride in gastrointestinal disorders. Drugs 2008; 68: 981-91.
40. Kusunoki H, Kusaka M, Kido S, et al. Comparison of the effects of omeprazole and famotidine in treatment of upper abdominal symptoms in patients with reflux esophagitis. J Gastroenterol 2009; 44: 261-70.
41. Veldhuyzen van Zanten SJ, Chiba N,. A randomized trial comparing omeprazole, ranitidine, cisapride, or placebo in helicobacter pylori negative, primary care patients with dyspepsia: the CADET-HN Study. Am J Gastroenterol 2005; 100: 1477-88.
42. Wysowski DK, Corken A, Gallo-Torres H, et al. Postmarketing reports of QT prolongation and ventricular arrhythmia in association with cisapride and Food and Drug Administration regulatory actions. Am J Gastroenterol 2001; 96: 1698-703.